MISSION Rx Act
- Bill Number
- H.R. 8667
- Origin Chamber
- House
- Congress
- 119th Congress, Session 2
- Policy Area
- Armed Forces and National Security
- Status
- Introduced
- Latest Action
- 2026-05-07: Referred to the Committee on Veterans' Affairs, and in addition to the Committee on Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Last Updated
- 2026-06-24T08:09:19Z
AI-Generated Summary
H.R. 8667 - MISSION Rx Act
Purpose
To limit out-of-pocket costs for certain prescription drugs under the TRICARE program (military health coverage) and Veterans Affairs (VA) system by tying them to Medicare Part D levels, and to cap prices federal agencies pay for these drugs, using prices negotiated under the Social Security Act's Drug Price Negotiation Program (a Medicare initiative for high-cost drugs).
Key Provisions
- TRICARE Cost-Sharing Cap (amends 10 U.S.C. § 1074g): For "selected drugs" under the Drug Price Negotiation Program, eligible beneficiaries' annual cost-sharing (copays or coinsurance) cannot exceed what Medicare Part D beneficiaries pay for the same drug that year.
- VA Copayment Cap (amends 38 U.S.C. § 1722A): Veterans' copayments for selected drugs are similarly capped at Medicare Part D levels during the negotiation program's coverage period.
- Federal Procurement Price Limit (amends 38 U.S.C. § 8126): Drug manufacturers' "master agreements" (contracts for supplying drugs to VA and certain other federal agencies) cannot set prices above the "maximum fair price" established by the Drug Price Negotiation Program for selected drugs. Applies to agreements in effect or entered after enactment.
- Application and Termination Rules: Caps apply during the negotiation program's existence; upon its end, agreements revert to prior pricing rules.
- Definitions: "Selected drug" and "maximum fair price" defined by reference to Social Security Act sections.
- Conforming Changes: Minor updates to Social Security Act to align references.
Significant Changes to Existing Law
- Introduces new caps on TRICARE and VA patient costs specifically for negotiated Medicare drugs, overriding prior cost-sharing rules.
- Adds pricing restrictions to VA's master agreement framework (previously focused on other pricing mechanisms), extending Medicare-negotiated prices to DoD, VA, and other federal drug purchases.
- First direct linkage of military/VA drug costs and procurement to Medicare's negotiation outcomes.
Potential Impacts
- Beneficiaries: Reduced out-of-pocket costs for TRICARE users (active-duty families, retirees) and VA-enrolled veterans on high-cost selected drugs, improving affordability.
- Government Agencies: Cost savings for Department of Defense (DoD), VA, and other federal entities through lower procurement prices; potential budget relief amid rising drug costs.
- Drug Manufacturers: Restricted ability to charge above Medicare-negotiated prices in federal contracts, possibly pressuring revenue from these sales.
- No direct international relations impact noted.
Main Stakeholders Affected
- TRICARE beneficiaries: Military personnel, families, and retirees.
- Veterans: VA pharmacy users.
- Federal agencies: DoD (TRICARE), VA, and others procuring drugs via master agreements.
- Pharmaceutical manufacturers: Those with selected drugs under negotiation.
- Medicare: Indirectly, as its negotiated prices set the benchmark.
Notable Legal, Constitutional, or Political Implications
- Legal: Builds on the 2022 Inflation Reduction Act's Drug Price Negotiation Program; ensures consistency across federal health programs without creating new negotiation authority. Applies retroactively to existing contracts, with termination safeguards.
- Constitutional: No apparent challenges; uses Congress's spending power over federal health benefits.
- Political: Sponsored by bipartisan group (e.g., Vindman, Ryan); promotes equity in federal drug pricing, potentially advancing broader drug cost reform debates. Referred to Veterans' Affairs and Armed Services Committees.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Rep. Vindman, Eugene Simon [D-VA-7]
Cosponsors (14)
Rep. Ryan, Patrick [D-NY-18], Rep. Houlahan, Chrissy [D-PA-6], Rep. Keating, William R. [D-MA-9], Rep. Goodlander, Maggie [D-NH-2], Rep. Deluzio, Christopher R. [D-PA-17], Rep. Moulton, Seth [D-MA-6], Del. Norton, Eleanor Holmes [D-DC-At Large], Rep. Stansbury, Melanie A. [D-NM-1], Rep. Quigley, Mike [D-IL-5], Rep. Khanna, Ro [D-CA-17], Rep. Budzinski, Nikki [D-IL-13], Rep. Carson, André [D-IN-7], Rep. Larsen, Rick [D-WA-2], Rep. Davids, Sharice [D-KS-3]
Recent Actions
- 2026-05-07: Referred to the Committee on Veterans' Affairs, and in addition to the Committee on Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2026-05-07: Referred to the Committee on Veterans' Affairs, and in addition to the Committee on Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2026-05-07: Introduced in House
- 2026-05-07: Introduced in House
Bill Versions
- Maximizing Individual Savings for Servicemembers In Obtaining Negotiated Rx Act — issued 2026-05-07 — PDF (6 pages)